Bilim, H&T Presspart, and Hovione Partner to Bring Asthma Product to the Turkish Market

September 1, 2020
BioPharm International Editors

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Bilim Pharmaceuticals, a Turkish pharmaceutical manufacturing and marketing company; H&T Presspart, a respiratory drug-delivery devices and components provider; and Hovione Technology, a pulmonary device technology development company, announced on Sept. 1, 2020 that they are collaborating to launch Bilim’s Ventofor Combi Fix, a formulation of Budesonide Formoterol for asthma and COPD management, delivered by the PowdAir Plus Dry Powder Inhaler (DPI).

According to a Hovione press release, the Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

“We are very happy to see that Bilim Pharmaceuticals has selected the PowdAir Plus DPI for their launch of Ventofor Combi Fix,” said Christian Kraetzig, H&T Presspart’s president, in the press release. “Due to the strong collaboration of Bilim Pharmaceuticals with Hovione Technology and H&T Presspart, this milestone could be reached. The individual expertise in each of their fields has allowed us to develop a strong partnership in the design, development, and manufacture of PowdAir Plus. We look forward to seeing Bilim Pharmaceuticals launch the product to the market and will continue to strongly support them with their inhalation strategy.”

Okan Oncel, Bilim Pharmaceuticals’s general manager, noted in the press release that the new product is an important part of their portfolio for asthma and chronic obstructive pulmonary disease treatment.

Hovione’s patented inhaler technology is globally available to pharmaceutical companies, said Peter Villax, Hovione Technology’s CEO, in the press release.

Source: Hovione